Here's What's Pushing Up Esperion Therapeutics Inc. Today
Shares of Esperion Therapeutics Inc. (NASDAQ: ESPR), a clinical-stage biotech focused on reducing cholesterol, popped up again this morning in response to top-line clinical trial results for its lead candidate. The stock was up 19.8% as of 11:10 a.m. EDT during Tuesday's session.
Esperion's wagons are tightly circled around bempedoic acid, its only drug in clinical trials at the moment. This morning, the company announced results from a 60-patient mid-stage study that met its main goal with flying colors.
Image source: Getty Images.
Source: Fool.com
Esperion Therapeutis.Inc. Aktie
1,72 €
4,51 %
Positive Community-Reaktionen für Esperion Therapeutis.Inc. mit einigen mehr Buy- als Sell-Einschätzungen.
Mit einem Community-Kursziel von 9 € für Esperion Therapeutis.Inc. wird ein starkes Wachstumspotenzial gegenüber dem aktuellen Kurs von 1.72 € gesehen.
